Scholarlink

<p>Self-replicating RNA vaccines delivered by viral replicon particles (VRPs) induce strong immunity, but repeated dosing on short intervals may be limited by vector responses. In patient samples and mice, VRP-srRNA vaccination generated VRP-neutralizing antibodies and T-cell responses to replicase. In mice, a third dose at two-week intervals minimally boosted transgene immunity, and prior VRP exposure reduced responses to a different-transgene VRP. Optimized schedules or heterologous prime–boost may sustain immunogenicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月16日

查看全文
  • Xingru Ma,
  • Robert D. Marek,
  • Susannah Gammell,
  • Amanda N. Summers,
  • Tao Wang,
  • Cong-Xiao Liu,
  • Gangjun Lei,
  • Junping Wei,
  • Erika J. Crosby,
  • Amy Hobeika,
  • H. Kim Lyerly,
  • Michael A. Morse,
  • Zachary C. Hartman

摘要

Self-replicating RNA vaccines delivered by viral replicon particles (VRPs) induce strong immunity, but repeated dosing on short intervals may be limited by vector responses. In patient samples and mice, VRP-srRNA vaccination generated VRP-neutralizing antibodies and T-cell responses to replicase. In mice, a third dose at two-week intervals minimally boosted transgene immunity, and prior VRP exposure reduced responses to a different-transgene VRP. Optimized schedules or heterologous prime–boost may sustain immunogenicity.